Hsbc Holdings PLC Takes $734,000 Position in Neogen Corporation $NEOG

Hsbc Holdings PLC bought a new position in Neogen Corporation (NASDAQ:NEOG) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 80,307 shares of the company’s stock, valued at approximately $734,000.

A number of other large investors have also bought and sold shares of NEOG. UMB Bank n.a. increased its holdings in Neogen by 238.2% during the 4th quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock valued at $45,000 after purchasing an additional 4,523 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Neogen by 816.9% in the fourth quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock worth $53,000 after purchasing an additional 6,764 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Neogen by 3,158.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company’s stock worth $58,000 after purchasing an additional 8,054 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Neogen during the fourth quarter worth $65,000. Finally, Merit Financial Group LLC bought a new stake in shares of Neogen during the fourth quarter worth $71,000. 96.73% of the stock is currently owned by institutional investors.

Neogen News Summary

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Neogen reported fiscal Q4 earnings of $0.09 per share, versus the $0.05 consensus estimate, while revenue of $225.3 million surpassed expectations of $212.35 million. The earnings result also improved substantially from the prior-year loss. Neogen Beats Q4 Earnings and Revenue Estimates
• Positive Sentiment: Above-consensus outlook: Management forecast fiscal 2027 revenue of $880 million to $885 million, well above the roughly $851.1 million analyst consensus. First-quarter fiscal 2027 revenue guidance of $207 million to $209 million also topped the $204.9 million consensus. The company outlined adjusted EBITDA guidance of $180 million to $182 million for fiscal 2027. Neogen Fiscal 2027 Outlook
• Neutral Sentiment: Investment may weigh on near-term profitability: Neogen plans to increase research and development spending by about 50%, signaling continued investment in future growth but potentially limiting margin expansion in the near term. Neogen Q4 Earnings Call Transcript
• Negative Sentiment: Revenue growth remained muted: Fiscal Q4 revenue was essentially flat year over year, declining 0.1%, so the stock’s positive reaction depends heavily on the earnings beat and forward guidance rather than current top-line growth.

Neogen Stock Up 22.7%

NASDAQ:NEOG opened at $11.53 on Friday. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -4.12, a P/E/G ratio of 4.21 and a beta of 1.80. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.84 and a current ratio of 3.92. The stock’s fifty day moving average price is $9.37 and its two-hundred day moving average price is $9.60. Neogen Corporation has a 52-week low of $4.56 and a 52-week high of $11.56.

Neogen (NASDAQ:NEOG) last released its earnings results on Thursday, July 30th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.05 by $0.04. The company had revenue of $225.30 million during the quarter, compared to analysts’ expectations of $212.35 million. Neogen had a positive return on equity of 2.35% and a negative net margin of 69.93%.The business’s revenue for the quarter was down .1% on a year-over-year basis. During the same period last year, the firm earned ($2.82) EPS. On average, analysts anticipate that Neogen Corporation will post 0.23 EPS for the current year.

Wall Street Analysts Forecast Growth

NEOG has been the subject of a number of research analyst reports. Wall Street Zen raised Neogen from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings lowered shares of Neogen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Neogen has an average rating of “Hold” and a consensus target price of $10.67.

Neogen Company Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.